Cheng et al. [20] reported that G-CSF therapy affects expression of matrix-metalloproteinases (MMP) and their tissue inhibitors (TIMP) leading to increased fibrosis, mortality and left ventricular dysfunction after MI in the long term. The gene discussed is CSF3; the disease is myocardial infarction.